US health experts said Tuesday they are halting clinical trials of convalescent blood plasma in patients with mild to moderate COVID symptoms after preliminary results showed no benefit from the treatment.
The trial that began in August involved just over 500 people who went to emergency rooms but did not need to be hospitalized.
The people chosen for the study also had risk factors such as obesity, high blood pressure, diabetes or heart trouble.
Some of them received the treatment—blood plasma from people who had COVID and overcame it—and others got a placebo.
Doctors looked at how many needed additional care or outright hospitalization, or who died, in the 15 days after undergoing the treatment.
An independent group of experts determined that while the convalescent plasma intervention caused no harm, it was unlikely to benefit patients, the National Institutes of Health said.
Convalescent plasma is the liquid part of blood from a COVID patient that recovered. It contains anti-bodies produced by the body after being infected.
In late October a study carried out in India and published in the medical journal BMJ said the treatment offered limited effectiveness.
It did not reduce mortality or keep people with moderate COVID symptoms from developing a serious case.
More than 100,000 people have received the treatment in the US since the start of the pandemic and many more elsewhere in the world, the NIH said.
In late August, at the persistent request of then president Donald Trump, the US Food and Drug Administration granted emergency authorization for transfusions of blood plasma from recovered COVID patients to people who were hospitalized with the disease.
The then head of the FDA, Stephen Hahn, acknowledged an error at a press conference with Trump, saying he had cited figures that overestimated the benefits of the treatment.
The FDA recently restricted its emergency authorization to use of plasma only with a high concentration of antibodies and for patients hospitalized with early stages of COVID or with a limited ability to produce antibodies.
Follow the latest news on the coronavirus (COVID-19) outbreak
© 2021 AFP
US halts trials of plasma transfusions for COVID patients (2021, March 3)
retrieved 3 March 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- Have Allergies? See If You’re at Risk for Severe COVID Vaccine Reaction - April 23, 2021
- A new method for fighting ‘cold’ tumors - April 23, 2021
- Mind Beauty on Why It's Harder to Wear a Mask in the Heat but Important Nonetheless - April 23, 2021
- Elevations RTC Highlights An Inclusive Campus Life - April 23, 2021
- The ThinOptics Vision Visionary: Gadi PontÃ - April 23, 2021
- A Plus From the Pandemic: Fewer Kids Using E-Cigarettes - April 23, 2021
- Double down on health and fitness with Garmin’s Venu 2 Series GPS smartwatch - April 23, 2021
- कोरोना संक्रमण चेन को तोड़ने में सहयोग करें जन-प्रतिनिधि: मुख्यमंत्री श्री चौहान - April 22, 2021
- Deepika Padukone’s 20-20-20 Fitness Mantra, Secret To Staying Slim Trim - April 22, 2021
- List of Top Pharma Companies in Chennai  - April 22, 2021